Long flights from Asmara to Amsterdam but finally made it in time for the kick off of the 2023 Alzheimer‘s Association International Conference. So many wonderful and familiar faces plus so much good research on display.  Kudos to the Gantenumab team for fully disclosing details regarding their failed trial.

Acumen presented top line results from INTERCEPT-AD trial. Data met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody. Data suggest target engagement and dose/exposure/CSF oligomer correlation without apparent safety concerns. 5 cases of ARIA-E (all asymptomatic) were observed and all were females. Interesting to note that the 2 fatal cases with lecanemab were also females. 

Alzheon presented two posters on 

1) Prevalence of Cerebral Microhemorrhages and Cortical Superficial Siderosis in APOE4/4 Homozygotes with Early Alzheimer's disease: Baseline Findings from Phase 3 Trial of Oral ALZ-801 in APOE4/4 Homozygotes (APOLLOE4) and

2. Reduction of Hippocampal Atrophy and Lateral Ventricle Enlargement Correlates with Clinical Benefit in APOE4 Carriers with Early AD: 1-Year Results from a Phase 2 Biomarker Study with Oral Anti-Amyloid Oligomer Inhibitor ALZ-801

Looking forward to another day of learning and networking.